Please enable JavaScript to continue using this application.

Compare $EVMN vs $KROS | Chartloom

Compare

$EVMN vs $KROS

Evommune Inc · Keros Therapeutics Inc

EVMN

Evommune Inc

KROS

Keros Therapeutics Inc

Compare $EVMN vs $KROS

Comparing Evommune Inc and Keros Therapeutics Inc

EVMNEvommune Inc

KROSKeros Therapeutics Inc

EVMNEvommune Inc

Market cap

$225M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-63.9%

52W performance

-69.1%

FCF yield

-55.4%

KROSKeros Therapeutics Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.6%

YTD performance

-35.5%

52W performance

-25.1%

FCF yield

-20.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EVMN

KROS

Detailed metrics comparison

EVMN

Evommune Inc

KROS

Keros Therapeutics Inc

Market Cap

EVMN$225M

KROS$236M

Enterprise Value

EVMN$166M

KROS$-21M

Price

EVMN$6.25

KROS$11.95

P/E Ratio

EVMNN/A

KROSN/A

P/S Ratio

EVMN14.07x

KROS15.75x

EV/Sales

EVMN10.38x

KROS-1.41x

EV/EBITDA

EVMN0.00x

KROS-0.47x

P/B Ratio

EVMN0.90x

KROS0.86x

P/FCF Ratio

EVMNN/A

KROSN/A

EV/FCF

EVMN-1.33x

KROS0.44x

PEG Ratio

EVMNN/A

KROSN/A

Forward P/E (NTM)

EVMNN/A

KROSN/A

Forward P/S (NTM)

EVMNN/A

KROSN/A

Revenue (TTM)

EVMN$16M

KROS$15M

Revenue Growth (YoY)

EVMNN/A

KROS-93.6%

Forward Rev Growth

EVMN881.5%

KROS-96.3%

Gross Margin (TTM)

EVMN0.0%

KROS0.0%

Operating Margin (TTM)

EVMN0.0%

KROS0.0%

EBITDA Margin (TTM)

EVMN-1097.9%

KROS-665.2%

Net Margin (TTM)

EVMN-943.2%

KROS-553.9%

FCF Margin (TTM)

EVMN-779.8%

KROS-322.9%

Net Income (TTM)

EVMN$-151M

KROS$-83M

FCF (TTM)

EVMN$-125M

KROS$-48M

EPS (TTM)

EVMN-$4.18

KROS-$4.20

ROE (TTM)

EVMN-4676.0%

KROS-2140.0%

ROA (TTM)

EVMN-4337.0%

KROS-1979.0%

ROIC (TTM)

EVMN-4661.0%

KROS-2140.0%

Cash

EVMN$60M

KROS$258M

Debt

EVMN$952K

KROS$0

Net Cash/Debt

EVMN$59M

KROS$258M

Current Ratio (TTM)

EVMN11.68x

KROS21.96x

Quick Ratio (TTM)

EVMN11.48x

KROS21.53x

Debt/Equity (TTM)

EVMN0.00x

KROS0.00x

Debt/Assets (TTM)

EVMN0.0%

KROS0.0%

Interest Coverage (TTM)

EVMNN/A

KROSN/A

Net Debt/EBITDA (TTM)

EVMN0.00x

KROS0.00x

Beta

EVMN0.62

KROS1.20

52W Performance

EVMN-69.1%

KROS-25.1%

YTD Performance

EVMN-63.9%

KROS-35.5%

% from 52W High

EVMN-81.2%

KROS-47.0%

% from 52W Low

EVMN3.8%

KROS23.3%

Asset Turnover (TTM)

EVMN0.00x

KROS0.06x

FCF Yield (TTM)

EVMN-55.4%

KROS-20.5%

Earnings Yield (TTM)

EVMN-67.0%

KROS-35.2%

Dividend Yield (TTM)

EVMNN/A

KROSN/A

Rule of 40

EVMN-779.8

KROS-416.5

EV/GP/RG

EVMNN/A

KROSN/A

Ticker research

View EVMN research View KROS research

Metric	EVMN Evommune Inc	KROS Keros Therapeutics Inc
Market & Valuation
Market Cap	$225M	$236M
Enterprise Value	$166M	$-21M
Price	$6.25	$11.95
P/E Ratio	N/A	N/A
P/S Ratio	14.07x	15.75x
EV/Sales	10.38x	-1.41x
EV/EBITDA	0.00x	-0.47x
P/B Ratio	0.90x	0.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.33x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$16M	$15M
Revenue Growth (YoY)	N/A	-93.6%
Forward Rev Growth	881.5%	-96.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1097.9%	-665.2%
Net Margin (TTM)	-943.2%	-553.9%
FCF Margin (TTM)	-779.8%	-322.9%
Net Income (TTM)	$-151M	$-83M
FCF (TTM)	$-125M	$-48M
EPS (TTM)	-$4.18	-$4.20
ROE (TTM)	-4676.0%	-2140.0%
ROA (TTM)	-4337.0%	-1979.0%
ROIC (TTM)	-4661.0%	-2140.0%
Financial Health
Cash	$60M	$258M
Debt	$952K	$0
Net Cash/Debt	$59M	$258M
Current Ratio (TTM)	11.68x	21.96x
Quick Ratio (TTM)	11.48x	21.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	1.20
52W Performance	-69.1%	-25.1%
YTD Performance	-63.9%	-35.5%
% from 52W High	-81.2%	-47.0%
% from 52W Low	3.8%	23.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.06x
FCF Yield (TTM)	-55.4%	-20.5%
Earnings Yield (TTM)	-67.0%	-35.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-779.8	-416.5
EV/GP/RG	N/A	N/A
Ticker research	View EVMN research	View KROS research

Valuation

P/S Ratio

EVMN

14.07x

KROS

15.75x

EV/FCF

EVMN

-1.33x

KROS

0.44x

Growth & revenue

Revenue Growth TTM

KROS

-93.6%

Forward Revenue Growth

EVMN

881.5%

KROS

-96.3%

Profitability & performance

Gross Margin

EVMN

0.0%

KROS

0.0%

ROE

KROS

-2140.0%

EVMN

-4676.0%

FCF Yield %

KROS

-20.5%

EVMN

-55.4%

52-Week Performance

KROS

-25.1%

EVMN

-69.1%

Detailed metrics comparison

EVMN

Evommune Inc

KROS

Keros Therapeutics Inc

Market Cap

EVMN$225M

KROS$236M

Enterprise Value

EVMN$166M

KROS$-21M

Price

EVMN$6.25

KROS$11.95

P/E Ratio

EVMNN/A

KROSN/A

P/S Ratio

EVMN14.07x

KROS15.75x

EV/Sales

EVMN10.38x

KROS-1.41x

EV/EBITDA

EVMN0.00x

KROS-0.47x

P/B Ratio

EVMN0.90x

KROS0.86x

P/FCF Ratio

EVMNN/A

KROSN/A

EV/FCF

EVMN-1.33x

KROS0.44x

PEG Ratio

EVMNN/A

KROSN/A

Forward P/E (NTM)

EVMNN/A

KROSN/A

Forward P/S (NTM)

EVMNN/A

KROSN/A

Revenue (TTM)

EVMN$16M

KROS$15M

Revenue Growth (YoY)

EVMNN/A

KROS-93.6%

Forward Rev Growth

EVMN881.5%

KROS-96.3%

Gross Margin (TTM)

EVMN0.0%

KROS0.0%

Operating Margin (TTM)

EVMN0.0%

KROS0.0%

EBITDA Margin (TTM)

EVMN-1097.9%

KROS-665.2%

Net Margin (TTM)

EVMN-943.2%

KROS-553.9%

FCF Margin (TTM)

EVMN-779.8%

KROS-322.9%

Net Income (TTM)

EVMN$-151M

KROS$-83M

FCF (TTM)

EVMN$-125M

KROS$-48M

EPS (TTM)

EVMN-$4.18

KROS-$4.20

ROE (TTM)

EVMN-4676.0%

KROS-2140.0%

ROA (TTM)

EVMN-4337.0%

KROS-1979.0%

ROIC (TTM)

EVMN-4661.0%

KROS-2140.0%

Cash

EVMN$60M

KROS$258M

Debt

EVMN$952K

KROS$0

Net Cash/Debt

EVMN$59M

KROS$258M

Current Ratio (TTM)

EVMN11.68x

KROS21.96x

Quick Ratio (TTM)

EVMN11.48x

KROS21.53x

Debt/Equity (TTM)

EVMN0.00x

KROS0.00x

Debt/Assets (TTM)

EVMN0.0%

KROS0.0%

Interest Coverage (TTM)

EVMNN/A

KROSN/A

Net Debt/EBITDA (TTM)

EVMN0.00x

KROS0.00x

Beta

EVMN0.62

KROS1.20

52W Performance

EVMN-69.1%

KROS-25.1%

YTD Performance

EVMN-63.9%

KROS-35.5%

% from 52W High

EVMN-81.2%

KROS-47.0%

% from 52W Low

EVMN3.8%

KROS23.3%

Asset Turnover (TTM)

EVMN0.00x

KROS0.06x

FCF Yield (TTM)

EVMN-55.4%

KROS-20.5%

Earnings Yield (TTM)

EVMN-67.0%

KROS-35.2%

Dividend Yield (TTM)

EVMNN/A

KROSN/A

Rule of 40

EVMN-779.8

KROS-416.5

EV/GP/RG

EVMNN/A

KROSN/A

Ticker research

View EVMN research View KROS research

Metric	EVMN Evommune Inc	KROS Keros Therapeutics Inc
Market & Valuation
Market Cap	$225M	$236M
Enterprise Value	$166M	$-21M
Price	$6.25	$11.95
P/E Ratio	N/A	N/A
P/S Ratio	14.07x	15.75x
EV/Sales	10.38x	-1.41x
EV/EBITDA	0.00x	-0.47x
P/B Ratio	0.90x	0.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.33x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$16M	$15M
Revenue Growth (YoY)	N/A	-93.6%
Forward Rev Growth	881.5%	-96.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1097.9%	-665.2%
Net Margin (TTM)	-943.2%	-553.9%
FCF Margin (TTM)	-779.8%	-322.9%
Net Income (TTM)	$-151M	$-83M
FCF (TTM)	$-125M	$-48M
EPS (TTM)	-$4.18	-$4.20
ROE (TTM)	-4676.0%	-2140.0%
ROA (TTM)	-4337.0%	-1979.0%
ROIC (TTM)	-4661.0%	-2140.0%
Financial Health
Cash	$60M	$258M
Debt	$952K	$0
Net Cash/Debt	$59M	$258M
Current Ratio (TTM)	11.68x	21.96x
Quick Ratio (TTM)	11.48x	21.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	1.20
52W Performance	-69.1%	-25.1%
YTD Performance	-63.9%	-35.5%
% from 52W High	-81.2%	-47.0%
% from 52W Low	3.8%	23.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.06x
FCF Yield (TTM)	-55.4%	-20.5%
Earnings Yield (TTM)	-67.0%	-35.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-779.8	-416.5
EV/GP/RG	N/A	N/A
Ticker research	View EVMN research	View KROS research